SIMCERE PHARMAC. GRP LTD Cash Flow-to-Debt Ratio
SIMCERE PHARMAC. GRP LTD cash flow-to-debt ratio. SIMCERE PHARMAC. GRP LTD (S2P) has a Cash Flow-to-Debt Ratio of 0.38x as of December 2025, meaning its operating cash flow of €2.01 Billion could theoretically repay 0% of its total liabilities (€5.31 Billion) in one year. Check SIMCERE PHARMAC. GRP LTD (S2P) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of SIMCERE PHARMAC. GRP LTD (2021–2025)
Cash flow-to-debt ratio of SIMCERE PHARMAC. GRP LTD from 2021 to 2025. Historical debt coverage capacity for SIMCERE PHARMAC. GRP LTD across 5 annual periods. Check SIMCERE PHARMAC. GRP LTD total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
SIMCERE PHARMAC. GRP LTD Cash Flow-to-Debt Ratio by Year (2021–2025)
SIMCERE PHARMAC. GRP LTD cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for SIMCERE PHARMAC. GRP LTD. For the full cash flow conversion analysis, see SIMCERE PHARMAC. GRP LTD (S2P) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.38x | €2.01 Billion | €5.31 Billion | ▲ +21.1% |
| 2024 | 0.31x | €1.39 Billion | €4.44 Billion | ▲ +652.8% |
| 2023 | 0.04x | €151.05 Million | €3.63 Billion | ▼ -88.8% |
| 2022 | 0.37x | €1.35 Billion | €3.64 Billion | ▲ +781.0% |
| 2021 | -0.05x | €-201.97 Million | €3.70 Billion | — |